APL
MCID: LKM067
MIFTS: 52

Leukemia, Acute Promyelocytic, Somatic (APL) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Leukemia, Acute Promyelocytic, Somatic

Aliases & Descriptions for Leukemia, Acute Promyelocytic, Somatic:

Name: Leukemia, Acute Promyelocytic, Somatic 54 54
Acute Promyelocytic Leukemia 54 12 50 24 25 56 29 14 69
Leukemia, Acute Promyelocytic 54 25 13
Aml M3 50 25 56
Acute Myeloid Leukemia with T(15;17)(q22;q12);(pml/raralpha) and Variants 50 56
Aml with T(15;17)(q22;q12);(pml/raralpha) and Variants 50 56
Acute Myeloblastic Leukemia Type 3 12 50
Acute Myeloblastic Leukemia 3 50 56
Apml 50 56
Apl 12 25
Leukemia, Promyelocytic, Acute 42
Leukemia Promyelocytic Acute 52
Myeloid Leukemia, Acute, M3 25
Acute Myeloid Leukemia M3 12
M3 Anll 25

Characteristics:

Orphanet epidemiological data:

56
acute promyelocytic leukemia
Prevalence: 1-9/1000000 (United States),1-9/1000000 (Europe),1-9/1000000 (France); Age of onset: Adult; Age of death: elderly;

HPO:

32
leukemia, acute promyelocytic, somatic:
Inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:0060318
ICD10 33 C92.4 C92.40
MeSH 42 D015473
NCIt 47 C3182
SNOMED-CT 64 110004001 28950004
Orphanet 56 ORPHA520
UMLS via Orphanet 70 C0023487
MESH via Orphanet 43 D015473
ICD10 via Orphanet 34 C92.4
UMLS 69 C0023487

Summaries for Leukemia, Acute Promyelocytic, Somatic

NIH Rare Diseases : 50 acute promyelocytic leukemia (apl) is an aggressive type of acute myeloid leukemia in which there are too many immature blood-forming cells (promyelocytes) in the blood and bone marrow. this build up of promyelocytes leads to a shortage of normal white and red blood cells and platelets in the body. the signs and symptoms of apl include an increased risk to both bleed and form blood clots. individuals may also experience excessive tiredness, pain in affected areas, loss of appetite, and weight loss. apl usually occurs in middle-aged adults, but can be diagnosed at any age. it is caused by a mutation that is acquired over a person's lifetime, usually involving a translocation between chromosomes 15 and 17. treatment may include the use of all-trans retinoic acid (atra) and arsenic trioxide or anthracycline-based chemotherapy. last updated: 1/18/2017

MalaCards based summary : Leukemia, Acute Promyelocytic, Somatic, also known as acute promyelocytic leukemia, is related to antiphospholipid syndrome and acute promyelocytic leukemia numa/rara type, and has symptoms including abnormality of cells of the granulocytic lineage and acute promyelocytic leukemia. An important gene associated with Leukemia, Acute Promyelocytic, Somatic is STAT5B (Signal Transducer And Activator Of Transcription 5B), and among its related pathways/superpathways are Gene Expression and Cytokine Signaling in Immune system. The drugs Trisenox and Arsenic trioxide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Disease Ontology : 12 An acute myeloid leukemia characterized by accumulation of promyelocytes in the bone marrow and by a translocation between chromosomes 15 and 17.

Genetics Home Reference : 25 Acute promyelocytic leukemia is a form of acute myeloid leukemia, a cancer of the blood-forming tissue (bone marrow). In normal bone marrow, hematopoietic stem cells produce red blood cells (erythrocytes) that carry oxygen, white blood cells (leukocytes) that protect the body from infection, and platelets (thrombocytes) that are involved in blood clotting. In acute promyelocytic leukemia, immature white blood cells called promyelocytes accumulate in the bone marrow. The overgrowth of promyelocytes leads to a shortage of normal white and red blood cells and platelets in the body, which causes many of the signs and symptoms of the condition.

OMIM : 54 The PML tumor suppressor protein is essential for the formation of a dynamic macromolecular nuclear structure called... (102578) more...

Related Diseases for Leukemia, Acute Promyelocytic, Somatic

Graphical network of the top 20 diseases related to Leukemia, Acute Promyelocytic, Somatic:



Diseases related to Leukemia, Acute Promyelocytic, Somatic

Symptoms & Phenotypes for Leukemia, Acute Promyelocytic, Somatic

Clinical features from OMIM:

612376 102578

Human phenotypes related to Leukemia, Acute Promyelocytic, Somatic:

32
id Description HPO Frequency HPO Source Accession
1 abnormality of cells of the granulocytic lineage 32 HP:0012135
2 acute promyelocytic leukemia 32 HP:0004836

GenomeRNAi Phenotypes related to Leukemia, Acute Promyelocytic, Somatic according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.87 STAT5B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.87 FLT3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.87 NCOR1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.87 FLT3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.87 NUMA1 STAT5B FLT3 NCOR1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.87 FLT3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.87 FLT3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.87 STAT5B FLT3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.87 STAT5B
10 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.87 NCOR1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.87 NCOR1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-158 9.87 NUMA1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.87 FLT3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.87 NUMA1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.87 STAT5B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.87 NUMA1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.87 STAT5B
18 Increased shRNA abundance (Z-score > 2) GR00366-A-215 9.87 NUMA1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.87 NCOR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.87 FLT3
21 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.87 STAT5B
22 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.87 NCOR1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.87 NUMA1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.87 STAT5B
25 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.87 NCOR1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.87 NUMA1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.87 STAT5B
28 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.87 FLT3
29 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.87 NUMA1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.87 NCOR1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.87 NUMA1

MGI Mouse Phenotypes related to Leukemia, Acute Promyelocytic, Somatic:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.25 CASP3 CYP26A1 FLT3 NCOR1 NCOR2 NPM1
2 growth/size/body region MP:0005378 10.11 CYP26A1 FLT3 NCOR1 NCOR2 NPM1 PRKAR1A
3 hematopoietic system MP:0005397 10.02 CASP3 FLT3 NCOR1 NCOR2 NPM1 PML
4 immune system MP:0005387 9.96 CASP3 FLT3 NCOR1 NCOR2 NPM1 PML
5 mortality/aging MP:0010768 9.73 CASP3 CYP26A1 FLT3 NCOR1 NCOR2 NPM1
6 liver/biliary system MP:0005370 9.7 STAT5B TBL1XR1 NCOR1 NCOR2 NPM1 PRKAR1A
7 neoplasm MP:0002006 9.1 FLT3 NPM1 PML PRKAR1A RARA ZBTB16

Drugs & Therapeutics for Leukemia, Acute Promyelocytic, Somatic

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Trisenox 17 46 ARSENIC TRIOXIDE Cell Therapeutics Approved September 2000

Drugs for Leukemia, Acute Promyelocytic, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1327-53-3 518740
2
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
3
Daunorubicin Approved Phase 4,Phase 3,Phase 2 20830-81-3 30323
4
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890
5
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 1 65271-80-9 4212
6
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
8
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
9
Thiotepa Approved Phase 4,Phase 1 52-24-4 5453
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3 50-02-2 5743
11
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 302-79-4 5538
12 Analgesics Phase 4,Phase 3,Phase 1
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
17 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
18 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
22 6-Mercaptopurine Phase 4,Phase 3,Phase 2
23 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
25 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Keratolytic Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Antilymphocyte Serum Phase 4,Phase 2
29 Antiemetics Phase 4,Phase 3,Phase 2
30 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
31 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
32 Autonomic Agents Phase 4,Phase 3,Phase 2
33 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
34 glucocorticoids Phase 4,Phase 3,Phase 2
35 Hormone Antagonists Phase 4,Phase 3,Phase 2
36 Hormones Phase 4,Phase 3,Phase 2
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
38 BB 1101 Phase 4,Phase 3
39 Dexamethasone 21-phosphate Phase 4,Phase 3
40 Dexamethasone acetate Phase 4,Phase 3 1177-87-3
41
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
42
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
43
Thioguanine Approved Phase 3 154-42-7 2723601
44
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
45
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
46
Amsacrine Approved Phase 3 51264-14-3 2179
47
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
48
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
49
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
50
Asparaginase Approved Phase 3 9015-68-3

Interventional clinical trials:

(show top 50) (show all 161)
id Name Status NCT ID Phase
1 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4
2 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Unknown status NCT00180128 Phase 4
3 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4
4 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Completed NCT00408278 Phase 4
5 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4
6 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
7 Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL Recruiting NCT01987297 Phase 4
8 A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia Enrolling by invitation NCT02200978 Phase 4
9 Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia Unknown status NCT00517712 Phase 2, Phase 3
10 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia Unknown status NCT00002701 Phase 3
11 Acute Promyelocytic Leukemia 2006 (APL) Unknown status NCT00378365 Phase 3
12 Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients Unknown status NCT01633099 Phase 3
13 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3
14 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
15 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Completed NCT00866918 Phase 3
16 S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00492856 Phase 3
17 Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00003934 Phase 3
18 Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission Completed NCT00962767 Phase 3
19 A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL) Completed NCT00591526 Phase 3
20 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia Completed NCT00003436 Phase 3
21 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
22 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
23 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3
24 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3
25 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3
26 APL93: Timing of CxT and Role of Maintenance Completed NCT00599937 Phase 3
27 Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Recruiting NCT02688140 Phase 3
28 Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) Recruiting NCT02899169 Phase 3
29 Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia Recruiting NCT02339740 Phase 3
30 Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia Recruiting NCT01226303 Phase 3
31 Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations Recruiting NCT02272478 Phase 3
32 Phase III Trial in Acute Promyelocytic Leukemia Patients Active, not recruiting NCT00482833 Phase 3
33 An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia Not yet recruiting NCT03151408 Phase 3
34 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
35 Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Unknown status NCT00675870 Phase 2
36 AIDA 2000 Guidelines Unknown status NCT01064570 Phase 2
37 FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML Unknown status NCT00559221 Phase 2
38 Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML Unknown status NCT00529880 Phase 2
39 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
40 Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia Completed NCT00008697 Phase 1, Phase 2
41 Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission Completed NCT00002609 Phase 2
42 Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00276601 Phase 2
43 Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia Completed NCT00016159 Phase 2
44 Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL Completed NCT00520208 Phase 2
45 All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab Completed NCT00413166 Phase 2
46 Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector Completed NCT01428128 Phase 2
47 Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible Completed NCT01361334 Phase 2
48 Study of Arsenic Trioxide in Small Cell Lung Cancer Completed NCT01470248 Phase 2
49 Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia Completed NCT00021242 Phase 2
50 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2

Search NIH Clinical Center for Leukemia, Acute Promyelocytic, Somatic

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: leukemia, promyelocytic, acute

Genetic Tests for Leukemia, Acute Promyelocytic, Somatic

Genetic tests related to Leukemia, Acute Promyelocytic, Somatic:

id Genetic test Affiliating Genes
1 Acute Promyelocytic Leukemia 29 24 RARA

Anatomical Context for Leukemia, Acute Promyelocytic, Somatic

MalaCards organs/tissues related to Leukemia, Acute Promyelocytic, Somatic:

39
Myeloid, Bone, Bone Marrow

Publications for Leukemia, Acute Promyelocytic, Somatic

Variations for Leukemia, Acute Promyelocytic, Somatic

Copy number variations for Leukemia, Acute Promyelocytic, Somatic from CNVD:

7 (show all 28)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17351 1 142487224 245120412 Gain Acute promyelocytic leukemia
2 29128 1 227843862 227867765 Deletion EGLN1 Acute promyelocytic leukemia
3 44777 10 62496958 68046104 Deletion Acute promyelocytic leukemia
4 71119 12 6755671 29248257 Deletion Acute promyelocytic leukemia
5 78273 13 49630676 50510777 Deletion DLEU7 Acute promyelocytic leukemia
6 78274 13 49630676 50510777 Deletion FAM10A4 Acute promyelocytic leukemia
7 78275 13 49630676 50510777 Deletion GUCY1B2 Acute promyelocytic leukemia
8 78767 13 56784440 114051465 Duplication Acute promyelocytic leukemia
9 93669 15 57244668 100182183 Duplication Acute promyelocytic leukemia
10 94970 15 72224840 100192115 Duplication Acute promyelocytic leukemia
11 108134 17 18901 21459693 Deletion Acute promyelocytic leukemia
12 108602 17 21491135 35542587 Duplication Acute promyelocytic leukemia
13 123386 18 7192739 7657575 Duplication PTPRM Acute promyelocytic leukemia
14 157044 21 1 48129895 Tri Acute promyelocytic leukemia
15 158722 21 36234195 46924583 Duplication Acute promyelocytic leukemia
16 181722 4 125190507 126521903 Deletion Acute promyelocytic leukemia
17 214094 6 5545437 8054930 Deletion Acute promyelocytic leukemia
18 220370 7 137795618 137920872 Translate TIF1 Acute promyelocytic leukemia
19 226739 7 61522282 158554645 Deletion Acute promyelocytic leukemia
20 228938 7 85414972 86445002 Deletion DMTF1 Acute promyelocytic leukemia
21 228939 7 85414972 86445002 Deletion GRM3 Acute promyelocytic leukemia
22 228940 7 85414972 86445002 Deletion KIAA1324L Acute promyelocytic leukemia
23 230737 8 1 146364022 Tri Acute promyelocytic leukemia
24 233093 8 122607785 132092760 Duplication Acute promyelocytic leukemia
25 254363 9 64207745 111479523 Deletion Acute promyelocytic leukemia
26 256567 9 94435025 94710006 Duplication C9orf3 Acute promyelocytic leukemia
27 256568 9 94435025 94710006 Duplication FBP1 Acute promyelocytic leukemia
28 256569 9 94435025 94710006 Duplication FBP2 Acute promyelocytic leukemia

Expression for Leukemia, Acute Promyelocytic, Somatic

Search GEO for disease gene expression data for Leukemia, Acute Promyelocytic, Somatic.

Pathways for Leukemia, Acute Promyelocytic, Somatic

GO Terms for Leukemia, Acute Promyelocytic, Somatic

Cellular components related to Leukemia, Acute Promyelocytic, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.89 CASP3 CD33 FIP1L1 FLT3 NABP1 NCOR1
2 nuclear body GO:0016604 9.76 NCOR2 SP100 SUMO1 ZBTB16
3 nuclear matrix GO:0016363 9.65 NCOR2 NUMA1 PML
4 PML body GO:0016605 9.56 PML SP100 SUMO1 ZBTB16
5 spindle microtubule GO:0005876 9.54 NCOR1 NUMA1 TBL1XR1
6 histone deacetylase complex GO:0000118 9.5 NCOR1 NCOR2 TBL1XR1
7 nucleoplasm GO:0005654 9.5 CASP3 FIP1L1 NABP1 NCOR1 NCOR2 NPM1
8 transcriptional repressor complex GO:0017053 9.46 NCOR1 NCOR2 TBL1XR1 ZBTB16
9 spindle pole centrosome GO:0031616 9.43 NPM1 NUMA1
10 cytosol GO:0005829 10.22 CASP3 FLT3 NABP1 NCOR1 NPM1 NUMA1

Biological processes related to Leukemia, Acute Promyelocytic, Somatic according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.89 NPM1 RARA SP100 TBL1XR1 ZBTB16
2 negative regulation of transcription, DNA-templated GO:0045892 9.85 PML RARA SUMO1 TBL1XR1 ZBTB16
3 negative regulation of cell proliferation GO:0008285 9.77 CD33 NPM1 PML RARA ZBTB16
4 regulation of lipid metabolic process GO:0019216 9.61 NCOR1 NCOR2 TBL1XR1
5 retinoic acid receptor signaling pathway GO:0048384 9.48 PML RARA
6 cellular lipid metabolic process GO:0044255 9.43 NCOR1 NCOR2 TBL1XR1
7 negative regulation of activated T cell proliferation GO:0046007 9.4 CASP3 PRKAR1A
8 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.32 NCOR1 NCOR2
9 response to estradiol GO:0032355 9.26 CASP3 NCOR2 RARA STAT5B
10 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.17 NCOR1 NCOR2 RARA SP100 SUMO1 TBL1XR1
11 PML body organization GO:0030578 9.16 PML SUMO1
12 regulation of transcription, DNA-templated GO:0006355 10.16 NCOR1 NCOR2 PML RARA SP100 STAT5B

Molecular functions related to Leukemia, Acute Promyelocytic, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.97 NABP1 NCOR1 NCOR2 PML RARA SP100
2 protein binding GO:0005515 9.93 CASP3 CD33 FIP1L1 FLT3 NABP1 NCOR1
3 transcription corepressor activity GO:0003714 9.55 NCOR1 NCOR2 RARA SP100 TBL1XR1
4 histone deacetylase binding GO:0042826 9.54 NCOR1 NCOR2 RARA
5 RNA polymerase II regulatory region DNA binding GO:0001012 9.26 NCOR2 RARA
6 glucocorticoid receptor binding GO:0035259 8.92 FLT3 NCOR2 STAT5B SUMO1

Sources for Leukemia, Acute Promyelocytic, Somatic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....